CEO and Chairman
University of Basel
Michael Hennig is a drug discovery Research Manager with 22 years of experience in pharmaceutical industry. He co-founded and is CEO and Chairman of the board of LeadXpro AG, an emerging biotech company and spin-out of the Paul Scherrer Institute (ETH, Switzerland) that is dedicated to structure based drug discovery of membrane protein targets. Formerly he worked 20 years at Roche research Basel as Global Head and Principle Leader of discovery technologies with responsibility for structure based drug discovery, protein science, assay development and HTS, corporate compound library, stem cell platform. In addition, he is guest Professor at the University of Basel in Structural Biology, gives lecture series in pharmacy, is author of more than 75 paper and lecturer at conferences, inventor of 8 patents in areas of technology, discovery and formulation of drug substances.
Structure based drug discovery on membrane protein targets: New developments and advancements